A cute myocardial infarction (AMI) and heart failure (HF) are characterized by an intense inflammatory response that contributes to progression of the injury and dysfunction (1) . Tissue injury stimulates the formation of the inflammasome and the production of interleukin (IL)-1b (2, 3) , the prototypical cytokine involved in virtually every local and systemic inflammatory response, also known as the "fever molecule" (4) (Figure 1 ).
In this issue of JACC: Basic to Translational
Science, Harouki et al. (5) show that neutralization of IL-1b using the monoclonal antibody gevokizumab initiated shortly after reperfusion (1 h) or late (7 days) significantly improved cardiac remodeling and systolic and diastolic function in nondiabetic as well as diabetic rats with AMI due to ischemia-reperfusion injury. Furthermore, when gevokizumab was administered 83 days after reperfusion, and when cardiac dilation and dysfunction had already Science author instructions page.
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providing a potential molecular mechanism. The reported effects of the IL-1b pathway in AMI are described in Figure 1 
